United States

Momenta Pharmaceuticals Inc (MNTA.OQ)

MNTA.OQ on NASDAQ Stock Exchange Global Select Market

26 Jul 2016
Change (% chg)

$-0.09 (-0.79%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for MNTA.OQ


Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox... (more)


Beta: 1.91
Market Cap(Mil.): $807.02
Shares Outstanding(Mil.): 70.92
Dividend: --
Yield (%): --


  MNTA.OQ Industry Sector
P/E (TTM): -- 41.28 37.71
EPS (TTM): -1.26 -- --
ROI: -26.90 -9.20 14.43
ROE: -30.08 -9.24 15.61

BRIEF-Momenta Pharmaceuticals appoints Steven Gilman to board of directors

* Momenta pharmaceuticals appoints steven c. Gilman, ph.d. To board of directors Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jun 23 2016

Momenta, Sandoz allowed to broaden claims over quality test patent

A federal judge has allowed Momenta Pharmaceuticals and Sandoz Inc to broaden a lawsuit accusing Amphastar Pharmaceuticals of infringing a patent on quality control methods used in making the blood thinner enoxaparin, the generic form of French drug maker Sanofi's Lovenox.

Jun 23 2016


Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
Provider : New Constructs, LLC
Provider : Thomson Reuters Stock Report
Provider : ValuEngine, Inc.
Provider : S&P Capital IQ Quantitative Report

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.